Streptococcal Infections - Pipeline Review, H1 2016

  • ID: 3775393
  • Drug Pipelines
  • 78 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Absynth Biologics Limited
  • AstraZeneca Plc
  • ContraFect Corporation
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • Merck & Co., Inc.
  • MORE
Streptococcal Infections - Pipeline Review, H1 2016

Summary

‘Streptococcal Infections - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections
- The report reviews pipeline therapeutics for Streptococcal Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Streptococcal Infections therapeutics and enlists all their major and minor projects
- The report assesses Streptococcal Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Streptococcal Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Streptococcal Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Streptococcal Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Absynth Biologics Limited
  • AstraZeneca Plc
  • ContraFect Corporation
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Streptococcal Infections Overview

Therapeutics Development

Pipeline Products for Streptococcal Infections - Overview

Pipeline Products for Streptococcal Infections - Comparative Analysis

Streptococcal Infections - Therapeutics under Development by Companies

Streptococcal Infections - Therapeutics under Investigation by Universities/Institutes

Streptococcal Infections - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Streptococcal Infections - Products under Development by Companies

Streptococcal Infections - Products under Investigation by Universities/Institutes

Streptococcal Infections - Companies Involved in Therapeutics Development

Absynth Biologics Limited

AstraZeneca Plc

Centauri Therapeutics Limited

ContraFect Corporation

Emergent BioSolutions Inc.

GlaxoSmithKline Plc

Helix BioMedix, Inc.

Merck & Co., Inc.

MGB Biopharma Limited

Sealife PHARMA GMBH

Sequoia Sciences, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Trellis Bioscience, Inc.

Wellstat Vaccines, LLC

Streptococcal Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ATx-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-6142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

firmocidin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

J8-CRM197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Group A Streptococcus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Coagulase for Streptococcus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides for Streptococcal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-295291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-369926 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

streptococcus [serotype B] (multivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes (30-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcal Infections - Dormant Projects

Streptococcal Infections - Discontinued Products

Streptococcal Infections - Product Development Milestones

Featured News & Press Releases

Aug 25, 2015: Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial

Jun 01, 2015: Researchers create new combination vaccine to fight Streptococcus A

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Streptococcal Infections, H1 2016

Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Streptococcal Infections - Pipeline by Absynth Biologics Limited, H1 2016

Streptococcal Infections - Pipeline by AstraZeneca Plc, H1 2016

Streptococcal Infections - Pipeline by Centauri Therapeutics Limited, H1 2016

Streptococcal Infections - Pipeline by ContraFect Corporation, H1 2016

Streptococcal Infections - Pipeline by Emergent BioSolutions Inc., H1 2016

Streptococcal Infections - Pipeline by GlaxoSmithKline Plc, H1 2016

Streptococcal Infections - Pipeline by Helix BioMedix, Inc., H1 2016

Streptococcal Infections - Pipeline by Merck & Co., Inc., H1 2016

Streptococcal Infections - Pipeline by MGB Biopharma Limited, H1 2016

Streptococcal Infections - Pipeline by Sealife PHARMA GMBH, H1 2016

Streptococcal Infections - Pipeline by Sequoia Sciences, Inc., H1 2016

Streptococcal Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Streptococcal Infections - Pipeline by Trellis Bioscience, Inc., H1 2016

Streptococcal Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Streptococcal Infections - Dormant Projects, H1 2016

Streptococcal Infections - Dormant Projects (Contd..1), H1 2016

Streptococcal Infections - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Streptococcal Infections, H1 2016

Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Absynth Biologics Limited
  • AstraZeneca Plc
  • ContraFect Corporation
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • Merck & Co., Inc.
  • MORE
Streptococcal Infections Streptococcal infections are caused by Streptococcus species. Streptococcal infections (strep for short) cause a variety of health problems. There are two types: group A and group B. Antibiotics are used to treat both. Streptococcus is a genus of spherical Gram-positive bacteria belonging to the phylum Firmicutes.

Streptococcal Infections pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 9 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 3 molecules, respectively.

Our latest report Streptococcal Infections – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Absynth Biologics Limited
AstraZeneca Plc
Centauri Therapeutics Limited
ContraFect Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Merck & Co., Inc.
MGB Biopharma Limited
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Trellis Bioscience, Inc.
Wellstat Vaccines, LLC
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll